Medically reviewed by DietsMD Board-Certified Physicians, Obesity Medicine
If you're researching GLP-1 weight loss medications, you've likely come across both semaglutide and tirzepatide. Both are FDA-approved, both are administered as weekly injections, and both produce significant weight loss. But they're not identical — and understanding the differences can help you and your physician choose the right medication for your goals. For a full overview of all GLP-1 options, read our GLP-1 weight loss guide.
Q: What is the difference between tirzepatide and semaglutide?
A: Semaglutide is a GLP-1 receptor agonist (single pathway), while tirzepatide is a dual GIP/GLP-1 receptor agonist (two pathways). Tirzepatide produces greater average weight loss in clinical trials — 20.9% vs. 15% for semaglutide — but both are highly effective options.
How They Work Differently
Semaglutide activates GLP-1 receptors in the brain and gut, suppressing appetite and slowing gastric emptying. It's a single-pathway medication with a well-established 7+ year safety record.
Tirzepatide activates both GLP-1 and GIP receptors simultaneously. The dual mechanism produces stronger appetite suppression and greater fat metabolism, which is why clinical trials show higher average weight loss.
Clinical Trial Results: The Numbers
Semaglutide (STEP trials, 68 weeks):
- Average weight loss: 15% of body weight
- 69% of patients lost 10%+ of body weight
- 50% of patients lost 15%+ of body weight
Tirzepatide (SURMOUNT trials, 72 weeks):
- Average weight loss: 20.9% of body weight (up to 22.5% at 15mg)
- 83% of patients lost 10%+ of body weight
- 57% of patients lost 20%+ of body weight
Side Effects: How Do They Compare?
Both medications share similar side effect profiles — primarily gastrointestinal and dose-dependent. Nausea, diarrhea, constipation, and vomiting are the most common with both. Clinical trials show comparable tolerability between the two medications, with most side effects resolving after the first few weeks at each dose level.
Q: Does tirzepatide cause more side effects than semaglutide?
A: Clinical trials show similar tolerability between the two medications. Both cause primarily GI side effects that are mild and dose-dependent. Individual response varies — some patients tolerate one better than the other.
Cost Comparison
Brand-name retail pricing (without insurance):
- Wegovy (semaglutide): ~$1,300–$1,600/month
- Zepbound (tirzepatide): ~$1,000–$1,300/month
DietsMD offers all-inclusive program pricing for both medications. Contact us for current rates.
Which Should You Choose?
Choose semaglutide if you want a medication with a longer clinical track record, or if tirzepatide isn't available in your area. Choose tirzepatide if you want the highest average weight loss potential and dual-mechanism action. The best choice is always made with a physician who knows your full health history.
Q: Which GLP-1 medication produces more weight loss?
A: Tirzepatide produces greater average weight loss in clinical trials — 20.9% vs. 15% for semaglutide. However, individual results vary significantly, and both medications are highly effective compared to non-medical weight loss approaches.
→ Read the Complete GLP-1 Weight Loss Guide
→ GLP-1 Weight Loss Results: What to Expect
→ How our medical weight loss program works
→ See If You Qualify for Oral Tirzepatide →
Medically reviewed by DietsMD board-certified physicians. Clinical data sourced from STEP and SURMOUNT trial publications.
